Assessment of the advantage of the serum S100B protein biomonitoring in the management of paediatric mild traumatic brain injury—PROS100B: protocol of a multicentre unblinded stepped wedge cluster randomised trial

Damien Bouvier (1, 2) , David Balayssac (1, 3) , Julie Durif (1) , Charline Mourgues (1) , Catherine Sarret (1) , Bruno Pereira (1) , Vincent Sapin (1, 2)

1 CHU Clermont-Ferrand
2 GReD - Génétique, Reproduction et Développement
3 Neuro-Dol - Neuro-Dol

Domaines: Biochimie [q-bio.BM]; Pédiatrie

Damien Bouvier, David Balayssac, Julie Durif, Charline Mourgues, Catherine Sarret, et al.. Assessment of the advantage of the serum S100B protein biomonitoring in the management of paediatric mild traumatic brain injury—PROS100B: protocol of a multicentre unblinded stepped wedge cluster randomised trial. BMJ Open, 2019, 9 (5), pp.e027365. ⟨10.1136/bmjopen-2018-027365⟩. ⟨hal-02237348⟩